Skip to content
PeptideHormone

TB-500

A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence.

Research peptidePreclinicalBased on Thymosin β4Compare with Tβ4 Compare lineage

A synthetic fragment sold under the name of the protein it came from. The parent biology is genuine; the fragment's own human evidence is not yet there.

Identity

Class
Synthetic thymosin β4 fragment / analog
Source
Synthetic; based on thymosin β4
Receptor
Same actin-related biology as thymosin β4 (not receptor-mediated)

Key properties

Evidence floorCommunityCOMM1
Half-life (native)
Poorly characterized in humans
COMMHalf-life is poorly characterized in humans. The figure is indicative of order-of-magnitude, not an established value.

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

TB-500 is a synthetic product based on thymosin β4 — often a specific active fragment — promoted for recovery and healing. Its rationale borrows from thymosin β4's actin and angiogenesis biology, but human clinical evidence specific to TB-500 is limited and preclinical.

Reference notes

  • TB-500 is derived from thymosin β4 but is not identical to the full endogenous peptide.
  • Its claims lean on thymosin β4 biology; direct human evidence for TB-500 is limited.
  • It is a 'research peptide' product — read the evidence honestly.

Common questions

What is TB-500?
A synthetic thymosin β4 fragment marketed for recovery; preclinical evidence. Structurally it is Synthetic thymosin β4 fragment / analog.
How does TB-500 work?
TB-500 is a synthetic product based on thymosin β4 — often a specific active fragment — promoted for recovery and healing. Its rationale borrows from thymosin β4's actin and angiogenesis biology, but human clinical evidence specific to TB-500 is limited and preclinical.
How strong is the evidence for TB-500?
PeptideHormone grades TB-500 at the "Preclinical" evidence tier — the evidence is largely animal or in-vitro, with human data thin or absent. It is catalogued as a community research peptide outside the approved-drug system, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of TB-500?
The reported circulating half-life of TB-500 is Poorly characterized in humans.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance · Sports medicine (Auckland, N.Z.), 2026 · PMID 41966639
  2. 2.Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians · The American journal of sports medicine, 2026 · PMID 41476424

External references

TB-500 in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.